How to Choose an Addiction Treatment Marketing Agency

HHS guidance is unambiguous: with limited exceptions, written authorization is required before protected health information can be used or disclosed for marketing purposes ⁷. That single sentence carries most of the operational weight an agency will face on a treatment-center engagement.

The failure mode is rarely outright disclosure of records. It is the slow drift toward using PHI-adjacent material without authorization:

• Patient testimonial videos pulled from alumni events.
• Before-and-after stories repurposed from intake notes.
• Retargeting pixels firing on confirmation pages that signal a completed inquiry.
• Case-management quotes lifted into landing-page copy.

Each of these can constitute a marketing use of PHI without the written authorization the rule requires.

A qualified agency will not treat this as a legal afterthought handed to the center’s counsel. It will have a documented intake process for any patient-derived content: who signed what, when authorization was obtained, the specific uses authorized, and a revocation pathway. It will know that consent for clinical care is not consent for marketing use.

The diligence question is direct. Ask the agency to walk through the last three patient stories it produced for any client and show the authorization documentation behind each. An agency that hedges, redirects to its compliance partner, or describes a verbal process has already answered.

Part 2 sits on top of HIPAA, not beside it. It applies to records identifying a patient as having received substance use disorder services from a Part 2 program, and it has historically imposed a stricter consent regime than HIPAA alone. The 2024 final rule reshapes that regime, and persons subject to the regulation must comply with the applicable requirements by February 16, 2026 ¹⁰. The rule was published in the Federal Register on February 16, 2024, with an effective date of April 16, 2024 ¹¹.

That deadline is a near-term diligence question, not a future planning item. An agency engaged today is building the data pipelines, consent flows, and creative workflows that will be audited against the final rule. Operators should ask candidates what specifically they are changing in their tracking, retargeting, CRM integration, and patient-content workflows to align with Part 2 by February 2026. Vague answers about “monitoring guidance” are disqualifying.

The full stack a candidate must operate within has four layers that overlap rather than substitute for each other:

• HIPAA governs marketing uses of PHI and the written authorization requirement ⁷.
• The 42 CFR Part 2 final rule governs SUD-specific records and consent, with the February 16, 2026 compliance date ^{10, 11}.
• FTC advertising substantiation governs the evidentiary basis for any claim the agency puts in front of consumers ⁸.
• OIG beneficiary inducement rules constrain what can be offered to influence a federal program beneficiary’s choice of provider, including limits on what cost-sharing waivers can be advertised at all ⁴.

An agency unfamiliar with any one of these layers is operating partially blind.

The FTC standard is older than most of the marketing tactics it now governs, and it applies to agencies directly, not only to advertisers. The policy statement makes clear that advertisers and ad agencies must have a reasonable basis for advertising claims before they are disseminated ⁹. The training material extends that to both express and implied claims that an ad conveys to reasonable consumers ⁸.

For addiction treatment, the live exposure surfaces are predictable:

• Success-rate percentages on landing pages.
• “Industry-leading outcomes” headlines in paid social.
• Recovery-rate comparisons against unnamed competitors.
• Star-rating aggregations pulled from selected review sources.

Each of these is a claim that requires competent and reliable evidence in the file before it goes live, and the agency carries part of that liability.

A diligence-ready candidate maintains a claims log: every quantitative or comparative statement that has appeared in client creative, the source documentation that substantiated it at the time, and the review cycle that retires claims when underlying data becomes stale. An agency that cannot produce a claims log on request is asking the operator to absorb the substantiation risk for every headline it writes. The question to ask in the first meeting is plain: show the substantiation file for the last outcome claim run for any treatment-center client.

The Beneficiary Inducements CMP applies when remuneration is offered to influence a federal health program beneficiary’s selection of a particular provider, and OIG has clarified that certain cost-sharing waivers cannot be offered as part of any advertisement or solicitation ⁴. For centers that bill Medicare or Medicaid for any service line, that constraint reaches directly into the creative brief.

The campaigns at risk are familiar:

• “Free detox” promotions running on paid search.
• Scholarship-bed offers featured in display creative without eligibility gating.
• Waived-copay headlines in retargeting.
• Gift cards or travel stipends framed as removing barriers to admission.

Some of these can be structured lawfully under specific exceptions; many cannot be advertised at all, regardless of how the underlying program is operated.

An agency operating without OIG fluency will treat these as conversion-rate experiments. An agency that understands the rule will ask, before drafting copy, which payer mix the campaign will reach, whether any federal program beneficiaries will see the offer, and whether the underlying financial arrangement fits an established exception. The diligence question: ask the candidate to describe an offer it declined to run for a prior client, and why. Silence is the answer.

Most agency dashboards report what is easy to count: form fills, phone calls, cost per lead, click-through rate. None of those numbers tell an operator whether the engagement is producing clinically appropriate admissions that stay long enough to generate outcomes or reimbursement. The NIH evidence is direct on this point: positive outcomes correlate with treatment retention and duration of treatment ¹³. Retention and adherence themselves serve as primary outcomes across numerous randomized clinical trials and observational studies in the addiction field ¹⁴.

That finding reorders the scoreboard. Inquiry-count KPIs (raw calls, CPL, form fills, click-through rate) describe traffic behavior. Retention-linked KPIs describe whether that traffic became a patient who completed enough treatment to benefit. The relevant set for an agency engagement looks different:

• Call-to-admit rate
• Admit-to-30-day retention
• Average length of stay by level of care
• Reimbursed days per admission

A diligence-ready agency reports CPL alongside call-to-admit and 30-day retention by campaign, by keyword cluster, and by creative variant. It can show which channels produce admits that stay and which produce calls that close at intake. That is the only reporting view that ties marketing spend to the clinical and financial reality of running a treatment program.

Each variable an operator already tracks responds to a different set of agency decisions. Mapping those decisions to the variable is the work of an honest scope-of-services conversation.

Organic visibility and paid keyword strategy move the top of the funnel. Broad terms (“rehab near me”) produce volume; clinically specific terms (“buprenorphine induction,” “dual diagnosis IOP”) produce inquiries that pre-qualify on level of care. An agency choosing the broader set will lower CPL and degrade call-to-admit. The trade is visible in the keyword report if the operator asks to see it.

Landing-page design moves call-to-admit. Pages that pre-disclose levels of care offered, payer acceptance, and what the first call covers produce callers who arrive at intake already qualified. Pages built for emotional conversion without those filters produce callers who disqualify in the first three minutes.

Call-handling handoff is where agency work intersects admissions-team work. If the agency controls the tracked number, the routing logic, and the after-hours flow, it owns part of the call-to-admit number. If routing dumps calls into voicemail after 6 p.m. or sends Spanish-language callers to an English-only queue, the agency is suppressing admits the marketing spend already paid for.

Retargeting and nurture sequences move admit-to-admit timing and reduce shop-around loss between inquiry and arrival. They also create the highest 42 CFR Part 2 exposure surface, which is why the same agency decisions that move this variable also determine whether the center is positioned for the February 16, 2026 compliance date ¹⁰.

Census quality is a payer-mix question before it is a marketing question. An agency that drives volume without regard to payer alignment can fill beds with admissions the center cannot reimburse at sustainable rates, or with inquiries for levels of care the center does not operate.

Medicare Part B covers intensive outpatient program services at certain facility types, including opioid treatment programs ¹². A center operating an IOP or OTP line has a defensible message to Medicare-eligible inquirers; a center without those service lines should not be running creative that implies coverage it cannot deliver. The same logic extends across commercial payers and Medicaid contracts.

The diligence question is whether the agency segments campaigns by payer and level of care, or runs one undifferentiated funnel and lets intake sort the wreckage. The first approach protects census quality. The second imports payer risk directly into the admissions pipeline.

The creative brief is where evidence-based treatment either survives translation into marketing or quietly disappears. NIDA’s research synthesis is explicit on three points an agency’s copy should reflect: care must be individualized, treatment duration must be adequate to produce outcomes, and medications such as methadone, buprenorphine, and naltrexone are effective for opioid use disorder ². Headlines that promise a uniform program, a fixed 30-day fix, or an abstinence-only path that erases medications are not stylistic choices. They are messaging that contradicts the clinical literature the center’s own program is built on.

Individualized care shows up in copy as differentiated landing pages by level of care, by primary substance, and by co-occurring presentation. A single “get help now” page for every inquiry collapses that differentiation and degrades the call-to-admit rate downstream.

Duration shows up as honest framing of length of stay by level of care, not as a countdown to graduation. Centers that advertise treatment as a discrete event rather than a phase of chronic-condition management create expectations that drive AMA departures in the first week.

Medications show up as named modalities for the service lines the center actually operates. An agency that writes around MAT because it tests poorly in focus groups is suppressing the most evidence-based offer a center has.

Three patterns in agency portfolios signal a messaging problem the operator will inherit.

1. The first is cure language: “break free,” “end addiction,” “permanent recovery.” These create unjustified medical expectations that AMA ethics guidance flags as a core advertising concern ¹, and they contradict NIDA’s framing of addiction as chronic and relapsing ².
2. The second is success-rate theater. Percentages presented without methodology, denominator, or follow-up window. Each of these is an advertising claim that requires competent and reliable evidence on file before dissemination ⁸, and the agency shares that substantiation burden.
3. The third is MAT erasure. Portfolios that show extensive creative for residential and detox but no campaigns naming buprenorphine, methadone, or naltrexone reveal an agency that defaults to what converts emotionally rather than what treats the condition. For any center operating an OTP or office-based buprenorphine line, that gap leaves the highest-evidence service line invisible in the funnel. Ask to see the last three pieces of creative the agency produced naming a specific medication. The portfolio answers the question.